Company code: Bloomage Biotechnology Corporation Limited(688363) company abbreviation: Bloomage Biotechnology Corporation Limited(688363) Bloomage Biotechnology Corporation Limited(688363)
Summary of annual report 2021
Section I important tips
1 the summary of this annual report comes from the full text of the annual report. In order to fully understand the company’s operating results, financial status and future development plan, investors should http://www.sse.com.cn. The website carefully reads the full text of the annual report. 2 major risk tips
During the reporting period, there were no major risks that had a material impact on the company’s production and operation. The company has described the relevant risks in detail in this report. See the corresponding contents on the company’s risk factors in “section III Management Discussion and analysis” for details. 3 the board of directors, the board of supervisors and the directors, supervisors and senior managers of the company guarantee the authenticity, accuracy and completeness of the contents of the annual report, and there are no false records, misleading statements or major omissions, and bear individual and joint legal liabilities. 4. All directors of the company attended the board meeting. 5. Zhitong Certified Public Accountants (special general partnership) has issued a standard unqualified audit report for the company. 6. The company is not profitable and has not yet achieved profitability when it is listed □ yes √ No 7. The profit distribution plan or the plan for the conversion of provident fund into share capital in the reporting period adopted by the resolution of the board of directors
In 2021, the company realized the net profit attributable to the shareholders of the listed company in the consolidated statement of 78233457348 yuan, and the parent company realized the net profit after tax of 99774528598 yuan. The company’s profit distribution plan for 2021 is as follows: the company plans to distribute cash dividends of 4.90 yuan (including tax) to all shareholders for every 10 shares based on the total share capital on the date of equity registration of dividend distribution in 2021, and the total amount of cash dividends is expected to be 23520000000 yuan, accounting for 30.06% of the net profit attributable to shareholders of Listed Companies in the consolidated statement of 2021, If the total share capital of the company changes before the equity registration date of equity distribution, it is proposed to maintain the amount of cash dividend distributed per share unchanged and adjust the total amount of distribution accordingly; The company does not convert the capital reserve into share capital and does not give bonus shares.
The 2021 profit distribution plan of the company has been deliberated and approved at the 29th meeting of the first board of directors of the company, and needs to be deliberated and approved by the 2021 annual general meeting of shareholders of the company. 8. Whether there are important matters such as special arrangements for corporate governance □ applicable √ not applicable
Section II basic information of the company
1 company profile company stock profile √ applicable □ not applicable
Company stock profile
Stock type stock exchange stock abbreviation before stock code change stock abbreviation and sector
A shares Shanghai Stock Exchange Bloomage Biotechnology Corporation Limited(688363) Bloomage Biotechnology Corporation Limited(688363) not applicable
Scientific innovation board
Profile of the company’s depositary receipts □ applicable √ not applicable contact person and contact information
Contact person and contact information secretary of the board of directors (domestic representative of information disclosure) securities affairs representative
Name: Li Yizheng, Dong Yi
Office address: floor 33, block D, Huaxi International Center, floor 33, block D, Jianguomenwai street, Chaoyang District, Beijing
Tel: 0108567060 Beijing Asiacom Information Technology Co.Ltd(301085) 670603
E-mail [email protected]. [email protected].
2. Introduction to the company’s main business in the reporting period (I) main business, main products or services
The company is a world-famous biotechnology company and bioactive material company. It is a hyaluronic acid whole industry chain platform enterprise integrating R & D, production and sales. The technology of microbial fermentation to produce hyaluronic acid is in the leading position in the world. Relying on the two technical platforms of microbial fermentation and cross-linking, as well as the six R & D platforms including pilot transformation platform, formula process R & D platform, synthetic biology R & D platform and application mechanism R & D platform, the company has established a whole industry chain business system of bioactive materials from raw materials to medical end products, functional skin care products and functional foods, serving the global medicine Manufacturing enterprises, medical institutions and end users in cosmetics, food and other fields. The company’s main products are as follows:
(1) Raw material products
Relying on the biological fermentation technology platform and industrialization advantages, the company has developed a series of bioactive products with hyaluronic acid as the core. Among them, hyaluronic acid includes more than 200 specifications of pharmaceutical grade, cosmetic grade and food grade products. It is widely used in the fields of drugs, medical devices, cosmetics, functional food and ordinary food, and involves new fields such as pets, reproductive health, oral cavity, fabrics and paper products. Other bioactive products include γ- Aminobutyric acid, polyglutamic acid sodium, otodin, ergosterol, micronucleus gel hydrogel, natto extract, brown rice fermentation filtrate, and micro beauty series.
The production of pharmaceutical grade raw materials of the company meets the requirements of American cGMP, Chinese GMP and ichq7, and has passed the on-site inspection of American FDA, Korean MFDs and Chinese GMP. Pharmaceutical grade sodium hyaluronate products have obtained 7 Registration qualifications in China; It has obtained 27 international registration and filing qualifications, including the European Union, the United States, South Korea, Canada, Japan, Russia and India (three pharmaceutical grade sodium hyaluronate products were registered in the United States DMF and one in South Korea DMF during the reporting period). The company will take advantage of a series of advantages in product R & D, quality management, sales channels, technical services and registration to meet future market opportunities. During the reporting period, relying on strong basic research and application basic research, combined with specific subdivided application scenarios, the company successfully listed bloomectotm medical device grade ekdoyne. The company’s food grade raw material production has ISO9001 and fssc22000 food safety system certification, and its products have kosher, halal and other registered qualification certification. It has advantages in quality management and technical support, and enjoys high recognition and popularity in the industry.
On January 7, 2021, the National Health Commission approved sodium hyaluronate declared by Bloomage Biotechnology Corporation Limited(688363) as a new food raw material, opening up a precedent for the application of HA in the field of ordinary food; In May 2021, the company was awarded the third Isee “excellent innovation practice Award”; Ultraha food grade sodium hyaluronate won the “innovation technology award”. The company’s food grade raw material product “ultraha sodium hyaluronate” won the “Product Innovation Award” in the “2021 fourth food science and technology innovation forum and 2021 great healthy food development forum” jointly sponsored by the magazine of food industry science and technology and food partner network. In October 2021, the company’s ultraha sodium hyaluronate won the “2021 food industry – Jung Technological Innovation Award” issued by Jung industrial media. In November 2021, in the “2021 new plant summit and nutrition smart manufacturing award ceremony” hosted by new nutrition, a well-known media in the food industry, the company won the “2021 new power award of raw materials”; In December 2021, Bloomage Biotechnology Corporation Limited(688363) led the completion of “high yield fermentation technology and industrial application of hyaluronic acid” and won the “first prize of science and technology award of China Food Industry Association”.
The innovation of raw materials is one of the underlying driving forces and fundamental sources of downstream end consumer goods innovation. The company is a strategic partner of global and local well-known cosmetics enterprises, providing customers with a full range of products and technical services, and constantly promoting the development of the cosmetics industry with the product innovation of new raw materials. During the reporting period, the company actively carried out product innovation and launched four new personal care raw material products, namely biobloom ™ Micro beauty Me-1 (developed based on probiotic fermentation platform with the function of regulating the balance of skin flora), hyacross ™ Hyaluronic acid bead tg300 (developed based on hyaluronic acid crosslinking platform, which can replace plastic beads and is suitable for the solution of frosting products for sensitive muscles), Xilan (by scientifically compounding a variety of active substances, it can protect the skin and effectively resist the damage of blue light to the skin), biobloom ™ Weimeitai Me-2 (epigenetic product with antioxidant function developed jointly with the academician team of Chinese Academy of engineering and obtained by relying on the company’s probiotic fermentation platform).
(2) Medical terminal products
The company independently develops and produces medical end products in the field of hyaluronic acid biomedical materials, which are mainly divided into medical beauty and medicine. Medicine includes ophthalmic viscoelastics, medical lubricants and other medical devices, as well as bone and joint cavity injection and other drugs. As the only general distributor of regenlab in China, the company continued to promote and sell the “sectorlet rich plasma preparation kit” (PRP) products in orthopedics, sports medicine, plastic surgery, pain and other departments in China in 2021.
Medical beauty includes soft tissue fillers, medical skin protectors, etc; In 2012, the company “run Baiyan” ®” The modified sodium hyaluronate gel for injection was approved as China’s first cross linked hyaluronic acid soft tissue filler with NMPA approval number. In 2016, the modified sodium hyaluronate gel containing lidocaine was first certified by NMPA. In 2019, the company launched the first self-developed single-phase hyaluronic acid containing hemp soft tissue filler in China; In the second half of 2020, the company launched Runzhi “baby needle”, a micro cross-linked hyaluronic acid product containing lidocaine, which is suitable for facial dermal tissue injection from shallow layer to middle layer for wrinkle removal. In 2021, the company upgraded the product of “microsphere crosslinked hyaluronic acid dermal skin activating product” “Yu Lian Zi Zi” product, which is suitable for the facial cross therapy and shallow micro injection micro crosslinking hyaluronic acid products, and set up a new benchmark in the field of facial rejuvenation, redefining the new concept of skin renewal. The company continues to enrich the product line of other hyaluronic acid fillers and upgrade the series of postoperative repair products, such as liquid dressing, spray dressing and other products. The company has the most complete category system of hyaluronic acid fillers. During the reporting period, according to the changing needs of the market, the company reorganized the medical beauty product system, arranged the injection product matrix according to different functions, different parts and different particle sizes, and comprehensively targeted layout of facial rejuvenation solutions, including fine line smoothing, depression filling, bone shaping, etc.
(3) Functional skin care products
Relying on the R & D system with microbial fermentation technology and cross-linking technology as the core, the company has deeply studied the effects of bioactive substances with different molecular weights such as hyaluronic acid, GABA and exedorin and their cross-linked derivatives on human skin, and taken this as the core component, with simplified formula, high content of active ingredients and strong targeted effect as the R & D direction, It has developed a series of functional skin care products for sensitive skin, damaged skin barrier, facial red blood, acne and other different skin problems. Based on the technology and experience accumulated in the biomedical industry for many years, the company uses the integrated blowing, filling and sealing technology to produce a series of small package “hyaluronic acid secondary throwing stock solution” products that are sterile and without chemical anti-corrosion addition. Through continuous upgrading of products, the publicity has fully launched the third generation of hyaluronic acid secondary throwing stock solution. At present, the company has many brands such as “BIOHYALUX”, “QUADHA”, “Mivel (MEDREPAIR)”, “BM muscle live”, “run hee Wo” (BLOOMCARE), and “BioBurgeon”, etc. the products include sub throwing liquid, all kinds of cream cream, mask, hand film, eye mask, spray, mother and child care. Scalp care and some makeup products.
(4) Functional food
For a long time, the company has been committed to applying food grade hyaluronic acid raw materials to ordinary food in China. With the empowerment of the “basic research and applied research” platform, the company has developed different types of bioactive raw materials for functional drinks, dietary supplements, dairy products and other fields. Under the trend of healthy upgrading of China’s food market, the company launched hyaluronic acid water brand “shuijiquan”, hyaluronic acid food brand “black zero” and hyaluronic acid fruit drink brand “no way corner” during the reporting period. At present, the company has established Wuxi functional food basic research center and Shanghai food R & D center. In the field of functional food R & D, the company focuses on beauty, joint health and sleep health.
（2） Main business model
1. Procurement mode
The main raw materials purchased by the company include peptone, yeast powder, glucose, ethanol, pre encapsulated syringes and packaging materials. The bidding and procurement center of the company is responsible for the management of supplier management system and procurement process, and supervising the procurement implementation process. The material procurement department is responsible for the procurement of materials and packaging materials used in the R & D and production of the company’s raw materials and end products. The company has a strict supplier management system. It will review qualified suppliers every year and establish a list of qualified suppliers. Each procurement demand department shall formulate its own demand plan according to the actual demand every month. The material procurement shall be coordinated according to the monthly material demand plan, and the arrival period shall be considered from all aspects (such as the supplier’s delivery date, cargo transportation mode, arrival period of imported goods, seasonal weather changes, etc.), so as to ensure the safety inventory of various materials, so as to ensure the cost, quality and timely delivery of purchased materials.
2. Production mode
The company mainly adopts the production mode of setting production according to sales, and prepares safety inventory according to market forecast. The main products are independently produced by the company, and some skin care products are outsourced by a third party; The products of revitacare, a French subsidiary, are produced by outsourcing. (1) Independent production
The company’s biological fermentation raw material products, medical end products and most functional skin care products are organized and produced by its own plant, production equipment and technical process. The strains required by the company’s biological fermentation raw material products are independently passed down and preserved by the company without purchasing from other parties. During the production process, the company organizes the production of API, drugs and medical device products in strict accordance with the requirements of drug GMP and medical device GMP. For functional protection
